Effects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials

International Journal of Endocrinology

Volumn 2016, Issue , 2016, Pages

  Unfer, Vittorio ^a   Nestler, John E ^b   Kamenov, Zdravko A ^c   Prapas, Nikos ^d   Facchinetti, Fabio ^e  

^a IPUS Institute of Higher Education   (Switzerland)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^d IAKENTRO   (Greece)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; ASTROMICIN; CHOLESTEROL; EPIMERASE; ESTRADIOL; FOLIC ACID; FOLLITROPIN; HIGH DENSITY LIPOPROTEIN; INHIBIN B; INOSITOL; LOW DENSITY LIPOPROTEIN; METFORMIN; PRASTERONE; PROLACTIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL;

AREA UNDER THE CURVE; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; HUMAN; INFERTILITY THERAPY; INSULIN SENSITIVITY; OOCYTE; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; OVARIAN STIMULATION; OVARY POLYCYSTIC DISEASE; OVULATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STIMULATION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84994558752     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2016/1849162     Document Type: Review

References (47)

1. The Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group, "Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS), " Human Reproduction, vol. 19, no. 1, pp. 41-47, 2004.
2. M. Ciampelli, A. M. Fulghesu, F. Cucinelli et al., "Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome, " Metabolism: Clinical and Experimental, vol. 48, no. 2, pp. 167-172, 1999.
3. A. D. Genazzani, C. Battaglia, B. Malavasi, C. Strucchi, F. Tortolani, and O. Gamba, "Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome, " Fertility and Sterility, vol. 81, no. 1, pp. 114-119, 2004.
4. A. Bigos, E. Palkowska, and D. Rosolowska-Huszca, "Effect of artificial and natural sweeteners on glucose and insulin in plasma of rats, " Journal of Pre-Clinical and Clinical Research, vol. 6, no. 2, pp. 93-97, 2012.
5. A. Dunaif, K. R. Segal, W. Futterweit, and A. Dobrjansky, "Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome, " Diabetes, vol. 38, no. 9, pp. 1165-1174, 1989.
6. J. S. E. Laven, A. G. M. G. J. Mulders, E. J. P. van Santbrink, M. J. C. Eijkemans, and B. C. J. M. Fauser, "PCOS: backgrounds, evidence and problems in diagnosing the syndrome, " International Congress Series, vol. 1279, pp. 10-15, 2005.
7. J. E. Nestler, "Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications, " Seminars in Reproductive Endocrinology, vol. 15, no. 2, pp. 111-122, 1997.
8. J. M. Lord, I. H. K. Flight, and R. J. Norman, "Metformin in polycystic ovary syndrome: systematic review and meta-analysis, " British Medical Journal, vol. 327, no. 7421, pp. 951-953, 2003.
9. R. Pasquali and A. Gambineri, "Insulin-sensitizing agents in polycystic ovary syndrome, " European Journal of Endocrinology, vol. 154, no. 6, pp. 763-775, 2006.
10. S. Gerli, M. Mignosa, and G. C. Di Renzo, "Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial, " European Review for Medical and Pharmacological Sciences, vol. 7, no. 6, pp. 151-159, 2003.
11. S. Gerli, E. Papaleo, A. Ferrari, and G. C. di Renzo, "Randomized, double blind placebo-controlled trial: effects of myoinositol on ovarian function and metabolic factors in women with PCOS, " European Review forMedical and Pharmacological Sciences, vol. 11, no. 5, pp. 347-354, 2007.
12. M. J. Iuorno, D. J. Jakubowicz, J.-P. Baillargeon et al., "Effects of D-chiro-inositol in lean women with the polycystic ovary syndrome, " Endocrine Practice, vol. 8, no. 6, pp. 417-423, 2002.
13. J. E. Nestler, D. J. Jakubowicz, P. Reamer, R. D. Gunn, and G. Allan, "Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome, " The New England Journal of Medicine, vol. 340, no. 17, pp. 1314-1320, 1999.
14. V. Unfer, G. Carlomagno, G. Dante, and F. Facchinetti, "Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials, " Gynecological Endocrinology, vol. 28, no. 7, pp. 509-515, 2012.
15. J. E. Nestler and V. Unfer, "Reflections on inositol(s) for PCOS therapy: steps toward success, " Gynecological Endocrinology, vol. 31, no. 7, pp. 501-505, 2015.
16. J. E. Nestler, D. J. Jakubowicz, A. F. de Vargas, C. Brik, N. Quintero, and F. Medina, "Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycanmediators as the signal transduction system, " The Journal of Clinical Endocrinology & Metabolism, vol. 83, no. 6, pp. 2001-2005, 1998.
17. V. Unfer, G. Carlomagno, E. Papaleo, S. Vailati, M. Candiani, and J.-P. Baillargeon, "Hyperinsulinemia alters myoinositol to d-chiroinositol ratio in the follicular fluid of patients with PCOS, " Reproductive Sciences, vol. 21, no. 7, pp. 854-858, 2014.
18. G. Carlomagno, V. Unfer, and S. Roseff, "The D-chiro-inositol paradox in the ovary, " Fertility and Sterility, vol. 95, no. 8, pp. 2515-2516, 2011.
19. D. Heimark, J. McAllister, and J. Larner, "Decreased myoinositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls, " Endocrine Journal, vol. 61, no. 2, pp. 111-117, 2014.
20. A. D. Genazzani, C. Lanzoni, F. Ricchieri, and V. M. Jasonni, "Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome, " Gynecological Endocrinology, vol. 24, no. 3, pp. 139-144, 2008.
21. D. Costantino, G. Minozzi, F. Minozzi, and C. Guaraldi, "Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial, " European Review for Medical and Pharmacological Sciences, vol. 13, no. 2, pp. 105-110, 2009.
22. M. Nordio and E. Proietti, "The Combined therapy with myoinositol and D-Chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared tomyo-inositol supplementation alone, " European Review for Medical and Pharmacological Sciences, vol. 16, no. 5, pp. 575-581, 2012.
23. E. Benelli, S. Del Ghianda, C. Di Cosmo, and M. Tonacchera, "A combined therapy with myo-inositol and D-chiro-inositol improves endocrine parameters and insulin resistance in PCOS young overweight women, " International Journal of Endocrinology, vol. 2016, Article ID 3204083, 5 pages, 2016.
24. J. Adams, J. W. Polson, and S. Franks, "Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism, " British Medical Journal, vol. 293, pp. 355-359, 1986.
25. E. Papaleo, V. Unfer, J.-P. Baillargeon, F. Fusi, F. Occhi, and L. De Santis, "Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial, " Fertility and Sterility, vol. 91, no. 5, pp. 1750-1754, 2009.
26. L. Ciotta, M. Stracquadanio, I. Pagano, A. Carbonaro, M. Palumbo, and F. Gulino, "Effects of Myo-Inositol supplementation on oocyte's quality in PCOS patients: a double blind trial, " European Review forMedical and Pharmacological Sciences, vol. 15, no. 5, pp. 509-514, 2011.
27. E. Raffone, P. Rizzo, and V. Benedetto, "Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women, " Gynecological Endocrinology, vol. 26, no. 4, pp. 275-280, 2010.
28. R. Isabella and E. Raffone, "Does ovary need D-chiro-inositol?" Journal of Ovarian Research, vol. 5, no. 1, article 14, 2012.
29. V. Unfer, G. Carlomagno, P. Rizzo, E. Raffone, and S. Roseff, "Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial, " European Review for Medical and Pharmacological Sciences, vol. 15, no. 4, pp. 452-457, 2011.
30. S. Colazingari, M. Treglia, R. Najjar, and A. Bevilacqua, "The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results froma randomized controlled trial, " Archives of Gynecology and Obstetrics, vol. 288, no. 6, pp. 1405-1411, 2013.
31. T. T. Y. Chiu, M. S. Rogers, E. L. K. Law, C. M. Briton-Jones, L. P. Cheung, and C. J. Haines, "Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality, " Human Reproduction, vol. 17, no. 6, pp. 1591-1596, 2002.
32. E. Papaleo, V. Unfer, J.-P. Baillargeon et al., "Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction, " Gynecological Endocrinology, vol. 23, no. 12, pp. 700-703, 2007.
33. I. Asplin, G. Galasko, and J. Larner, "Chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol-and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects, " Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 13, pp. 5924-5928, 1993.
34. A. S. Kennington, C. R. Hill, J. Craig et al., "Low urinary chiroinositol excretion in non-insulin-dependent diabetes mellitus, " The New England Journal of Medicine, vol. 323, no. 6, pp. 373-378, 1990.
35. A. Bevilacqua, G. Carlomagno, S. Gerli et al., "Results from the International Consensus Conference on myo-inositol and Dchiro-inositol in Obstetrics and Gynecology-assisted reproduction technology, " Gynecological Endocrinology, vol. 31, no. 6, pp. 441-446, 2015.
36. J. Larner, L. C. Huang, C. F. W. Schwartz et al., "Rat liver insulin mediator which stimulates pyruvate dehydrogenase phosphatase contains galactosamine and D-chiroinositol, " Biochemical and Biophysical Research Communications, vol. 151, no. 3, pp. 1416-1426, 1988.
37. L. C. Huang, M. C. Fonteles, D. B. Houston, C. Zhang, and J. Larner, "Chiroinositol deficiency and insulin resistance. III. Acute glycogenic and hypoglycemic effects of two inositol phosphoglycan insulin mediators in normal and streptozotocindiabetic rats in vivo, " Endocrinology, vol. 132, no. 2, pp. 652-657, 1993.
38. T. T. Y. Chiu, M. S. Rogers, C. Briton-Jones, and C. Haines, "Effects of myo-inositol on the in-vitro maturation and subsequent development of mouse oocytes, " Human Reproduction, vol. 18, no. 2, pp. 408-416, 2003.
39. M. Matsuda, K. Tsutsumi, T. Kanematsu et al., "Involvement of phospholipase C-related inactive protein in the mouse reproductive system through the regulation of gonadotropin levels, " Biology of Reproduction, vol. 81, no. 4, pp. 681-689, 2009.
40. J.-P. Baillargeon, J. E. Nestler, R. E. Ostlund, T. Apridonidze, and E. Diamanti-Kandarakis, "Greek hyperinsulinemicwomen, with or without polycystic ovary syndrome, display altered inositols metabolism, " Human Reproduction, vol. 23, no. 6, pp. 1439-1446, 2008.
41. J.-P. Baillargeon, M. J. Iuorno, T. Apridonidze, and J. E. Nestler, "Uncoupling between insulin and release of a d-chiro-inositolcontaining inositolphosphoglycan mediator of insulin action in obese women with polycystic ovary syndrome, " Metabolic Syndrome and Related Disorders, vol. 8, no. 2, pp. 127-135, 2010.
42. J.-P. Baillargeon, E. Diamanti-Kandarakis, R. E. Ostlund Jr., T. Apridonidze, M. J. Iuorno, and J. E. Nestler, "Altered D-chiroinositol urinary clearance in women with polycystic ovary syndrome, " Diabetes Care, vol. 29, no. 2, pp. 300-305, 2006.
43. P. T. Goud, A. P. Goud, P. Van Oostveldt, and M. Dhont, "Presence and dynamic redistribution of type I inositol 1, 4, 5-trisphosphate receptors in human oocytes and embryos during in-vitro maturation, fertilization and early cleavage divisions, "Molecular Human Reproduction, vol. 5, no. 5, pp. 441-451, 1999.
44. H. K. Ortmeyer, L. C. Huang, L. Zhang, B. C. Hansen, and J. Larner, "Chiroinositol deficiency and insulin resistance. II. Acute effects of D-chiroinositol administration in streptozotocin-diabetic rats, normal rats given a glucose load, and spontaneously insulin-resistant rhesus monkeys, " Endocrinology, vol. 132, no. 2, pp. 646-651, 1993.
45. M. Bizzarri andG. Carlomagno, "Inositol: history of an effective therapy for polycystic ovary syndrome, " European Review for Medical and Pharmacological Sciences, vol. 18, no. 13, pp. 1896-1903, 2014.
46. G. Carlomagno, S. De Grazia, V. Unfer, and F. Manna, "Myoinositol in a new pharmaceutical form: a step forward to a broader clinical use, " Expert Opinion on Drug Delivery, vol. 9, no. 3, pp. 267-271, 2012.
47. A. Bevilacqua and M. Bizzarri, "Physiological role and clinical utility of inositols in polycystic ovary syndrome, " Best Practice & Research Clinical Obstetrics & Gynaecology, 2016.